Cladribine for the treatment of secondary progressive MS - randomized, double-blind, placebo-controlled study.

Phase 2

Not yet recruiting

• Conditions: Multiple sclerosis secondary progressive form
• Interventions: Drug: Cladribine Subcutaneous Injection; Drug: 0.9% Chloride Injection Sodium

• Registration Number: 2024-516992-33-02
• Lead Sponsor: Instytut Psychiatrii I Neurologii

Brief Summary

The aim of the study is to evaluate the efficacy and safety of subcutaneously administered cladribine compared with placebo in patients with secondary progressive multiple sclerosis (SPMS) who have had progression in the last 24 months and no relapses within 12 months. Patients with or without MRI disease activity (patients with gadolinium enhancement lesions [T1Gd +] or new / increasing T2 lesions) will be enrolled in the study. The primary efficacy endpoint for subcutaneous administration of cladribine in SPMS patients will be slowing of brain volume loss relative to placebo.

Detailed Description

This is a randomized, placebo-controlled, double-blind, multi-center, phase 2 study of subcutaneous cladribine in non-relapsing, secondary progressive multiple sclerosis. Eligible patients will be randomly allocated in a 1:1 ratio to receive either placebo or subcutaneous cladribine at a dose of 1.8 mg/kg of body weight. The study will consist of three periods: screening, treatment, and follow-up. During the screening, the investigators will assess patient eligibility. During the treatment, cladribine will be given over 6 visit every 5-6 weeks. During the follow-up of 96 weeks, safety and efficacy assessments will be carried out on five visits: the first visit will take place 4 weeks after the last cladribine dose, and the remaining visits will take place every 24 weeks.

There will a rescue option of unblinding and treatment with a full dose of cladribine (cladribine arm) or approved medications (placebo arm) for patients with a severe relapse or ≥ 2 non-severe relapses after enrolment or with a substantial neuroimaging disease activity ≥ 4 Gd+ lesions in any scan, ≥ 3 Gd+ lesions in any two scans, ≥ 2 Gd+ lesions in any three scans, or ≥ 9 new/enlarging T2 lesions on any scan compared with baseline).

All raters will be blinded to treatment allocation. All neuroimaging examinations will be evaluated at a central neuroimaging unit by investigators blinded to treatment allocation.

Study type: interventional (clinical trial) Planned enrolment: 188 patients Allocation: randomized Masking: Double (Participant, Investigator) Primary purpose: Treatment Start Date: October 2022

Study design: The study aims to assess the safety and efficacy of subcutaneous cladribine in patients with SPMS who have not experienced relapses over a year and with or without active lesions on neuroimaging. The study will be randomized, placebo-controlled, and double blind. Because no treatment is approved for inactive SPMS, placebo was chosen as the comparator. Patients receiving other treatments for SPMS or immunosuppressant will not be included.

The study will consist of the following phases:

1. Screening phase (about 4 weeks)

2. Treatment phase, patients will be randomized 1:1 ratio of either cladribine 1,8mg/kg or placebo (30 weeks)

3. Follow-up phase , patients will be followed every 24 weeks for up to 122 weeks for safety and efficacy of the treatment;

Patients: The group of 188 patients fulfilling inclusion criteria and not-fulfilling exclusion criteria will enrolled to the study. All patient has to sign written informed consent form approved by Ethics Committee.

Blinding: Randomization and blinding will be done by "dual assessor" approach . Every site will have two teams of blinded and blinded investigators . The blinded investigators include Principal or treating investigators and rating investigators, as well as blinded treating nurse. The unblinded team includes: Randomizing investigator responsible also for laboratory assessment and unblinded nurse/pharmacist responsible for preparing drugs.

Intervention:

Experimental arm Drug: Cladribine at a dose of 1.8 mg/kg of body weight. Cladribine will be given subcutaneously over 6 visits every 5-6 weeks.

Comparator: Placebo matched to the subcutaneous injection of cladribine.

Follow-up: Patients will be assessed and baseline visit, and every 24 weeks over 24 months since the last dose of the interventional drug. The evaluations include:

1. Medical history, concomitant medication, relapse history

2. Physical examination, neurological examination

3. Clinical assessment: EDSS, T25FWT, 9-HPT,

4. MsQoL and CSSR scale

5. MRI of head and spinal cord (baseline, every 6 months for head and every 12 months for spinal cord)

6. Laboratory and biomarkers evaluation (hematology, coagulation, HIV serology, Hepatitis virus B and C serology, tuberculosis tests (Quantiferron test if necessary), ,

The primary end point will be percentage brain volume change between the last dose (week 24) and end of study (week 122). The primary endpoint was selected based on the widely discussed indications for designing studies in the SPMS. The main secondary clinical end points will assess the change in neurological function on the Expanded Disability Status Scale, Timed 25 Foot Walk, and 9-Hole Peg Test, which measures upper limb function. The change in cognitive function will be assessed with various neuropsychological tests. The main secondary neuroimaging end points will include change in the number of contrast-enhancing lesions, the number of T1-hypointesne lesions ("black holes"), and the volume of T2 lesions. The main exploratory end point will be the change in QSM rim+ lesions on brain neuroimaging; these lesions are markers of chronic, smoldering neuroinflammation that may take place behind an intact blood-brain barrier. Change in the concentrations of neurofilament light chain and glial fibrillary acidic protein, which are markers of brain tissue damage, will be main laboratory end points. An exploratory analysis of inflammatory protein biomarkers will be carried out in serum and cerebrospinal fluid of a selected patients (Luminex). The study will assess the safety of cladribine and its effect on quality of life.

The proposed intervention is well supported by the current evidence. Cladribine is among the few drugs that penetrate an intact blood-brain barrier, which allows action on lymphocytes resident in the central nervous system. The study will assess whether cladribine slows down disease progression clinically and it will use the best currently available indicators of disease progression: brain and cervical cord atrophy and the number of demyelinating lesions. Additionally, it will be assessed whether the presence of QSM rim+ lesions is associated with disease course and the therapeutic effect of cladribine. For example, a reduction in the number of these lesions during cladribine treatment would supports an action of the drug behind the blood-brain barrier. An association between QSM rim+ lesions and the therapeutic effect of cladribine could help select a subgroup of patients most likely to benefit from anti-inflammatory treatments. The measurement of serum biomarkers will enable an assessment of the activation of the peripheral immune system (cytokine, chemokines) and of the therapeutic effect of cladribine (NfL, GFAP). The positive results of the current project will allow the design of a phase 3 trial. A practical benefit of the proposed study is that patients with SPSM, who are currently not eligible for any treatment options, will have a choice to receive a potentially effective therapy, which costs substantially less compared to other therapies in MS.

Background: Multiple sclerosis (MS) is the most common chronic inflammatory, demyelinating disease of the central nervous system, with about 2.5 million patients worldwide, including 45 thousand in Poland. Most patients have relapsing-remitting MS (RRMS) at the start of the disease, in which neurological symptoms appear during relapses and may subside. There is a dozen of disease-modifying treatments for this form of the disease. Several years after the diagnosis of RRMS, the disease progresses into SPMS, in which disability worsens gradually independently of relapses. Patients with SPMS suffer from restricted mobility (need walking aids, wheelchair), cognitive impairment, (difficulties in workplace and in managing everyday life), depression, pain due to spasticity, chronic fatigue, lack of sphincter control, or sexual dysfunction. These patients need more medical help (office visits, rehabilitation, hospitalization), are more often unemployed, and have a lower quality of life than do patients with RRMS. Currently, three disease-modifying treatments are available for patients with SPMS in Europe: interferon beta-1b (low efficacy), mitoxantrone (serious adverse effects), and siponimod. However, these medications can be used only in patients with active disease, i.e., in those with still observed relapses or active brain lesions on magnetic resonance imaging. Therefore, about a half of patients with SPMS cannot receive any disease-modifying treatment. The current understanding of the pathogenesis of MS suggests that there are two types of neuroinflammation since disease onset. Type-1 neuroinflammation is characterized by an acute, focal infiltration of pathogenic lymphocytes and autoantibodies, which is associated with blood-brain barrier disruption. This type of neuroinflammation may be responsible for relapses and contrast-enhancing lesions. Type-2 neuroinflammation is a chronic, smoldering process that takes place behind a closed blood-brain barrier, and it is characterized by slowly expanding lesions and follicle-like lymph structures in the meninges, and diffuse inflammatory changes in white matter and cortex. Other characteristics of type-2 neuroinflammation include microglial and astroglial activation, delayed maturation of oligodendrocytes, and inhibition of remyelination. These processes cause disease progression independently of relapses. Both types of neuroinflammation occur simultaneously since disease onset, but type-2 neuroinflammation is thought to predominate in the secondary progressive phase. Standard neuroimaging methods cannot pinpoint lesions that are specific for type 2 neuroinflammation, but longitudinal brain atrophy and enlargement of lesions can indirectly measure its magnitude. Quantitative susceptibility mapping (QSM), a new imaging technique, can indicate chronic inflammatory lesions that are surrounded by active microglia at the lesion border. Microglia because of iron load form a hypointense rim, and might be thus shown by QSM technique (rim+ lesions). However, QSM is not currently used in clinical practice it is now recommended for use in clinical trials.

The currently available disease modifying-treatments for SPMS act solely or mainly on type-1 neuroinflammation, and because of that they are approved for patients with relapses or active lesions only. Cladribine is approved for the treatment of RRMS. Cladribine substantially decreases the number of contrast-enhancing lesions and relapse frequency in patients with RRMS (an effect on type-1 neuroinflammation). Cladribine may also act on type-2 neuroinflammation i.e. on the autoreactive lymphocytes resident in the central nervous system, including tertiary lymphoid structures, because cladribine penetrates into the central nervous system through an intact blood-brain barrier. The effect on type-2 neuroinflammation is supported by the observation that oligoclonal bands disappear in patients with RRMS and SPMS after cladribine treatment.

Study Timeline

• Study First Posted: 2025-01-30
• Last Update Posted: 2025-01-30

Recruitment & Eligibility

• Status: Authorised, recruitment pending
• Sex: Not specified
• Target Recruitment: 188

Inclusion Criteria

1. Written informed consent to participate in the study 2. Diagnosis of SPMS based on the 2017 McDonald criteria, with a relapsing-remitting course at the onset of the disease 3. History of progressive neurological deterioration within at least 24 months: Increase in EDSS score by at least 1 point if EDSS ≤ 5 and by at least 0.5 point if EDSS> 5. A summary written by the researcher explaining why he thinks the patient has progressive disease for at least 24 months. 4. No clinical relapses in the last 12 months 5. Baseline EDSS ≥ 3.5 and ≤ 7.5 6. Age 30-65 years 7. Time from first symptoms at least 10 years 8. For women of childbearing potential: a written declaration of discontinuation of heterosexual intercourse or use of contraception in the study and for at least 6 months after the last dose as defined below: a. The woman must stop heterosexual intercourse or use a contraceptive method with a failure rate <1% per year during treatment. Women are also not allowed to donate eggs during this period. b. A woman of childbearing potential is a woman who has had her first menstrual period, is premenopausal (uninterrupted period of at least 12 months without menstruation) and is not permanently sterile due to surgery (removal of the ovaries, fallopian tubes and / or uterus) or any other reason. found by the researcher. c. Examples of contraception with a failure rate <1% per year are bilateral tubal ligation, partner sterilization, hormonal contraception to suppress ovulation, hormone-secreting IUDs or copper IUDs. d. Hormonal contraception must be used in conjunction with a barrier method. e. Temporary abstinence, such as using a calendar method, is not an acceptable form of contraception. 9. For men: a written declaration to stop heterosexual intercourse in the study and for at least 6 months after the last dose, or to use condoms and contraception in female partners during this period as described above. In addition, statements on not donating semen during the study and for 6 months after the last dose of the drug. 10. Possibility of meeting the requirements of the test protocol in the opinion of the researcher.

Exclusion Criteria

1. Lack of consent to participate in the study 2. History of cladribine treatment regardless of indication 3. Hypersensitivity to any component of the investigational drug 4. The need to use other immunomodulating or immunosuppressive drugs, including drugs used in secondary progressive MS, e.g. interferon beta-1b, mitoxantrone, siponimod 5. Contraindications for performing magnetic resonance imaging 6. Pregnancy and the period of breastfeeding 7. Lack of consent to the use of effective methods of contraception as defined in the inclusion criteria 8. Diseases of the nervous system (brain or spinal cord tumors, stroke or spinal cord, brain or spinal cord injury, encephalomyelitis, vitamin B12 deficiency, other than multiple sclerosis demyelinating diseases of the central nervous system) 9. Serious accompanying diseases (e.g. cancer, liver and / or kidney failure, heart failure II and III according to NYHA) or other diseases which, in the opinion of the investigator, could threaten the patient's safety in the study or prevent compliance with the requirements of the study protocol 10. Disease relapse <12 months after screening visit 11. Chronic treatment with steroids or immunosuppressants (e.g. azathioprine, methotrexate, cyclosporine) <6 months prior to study entry 12. Disease-modifying therapies: a. Interferons, glatiramer acetate, and dimethyl fumarate must be withdrawn prior to inclusion in the study; they do not require a transition period; b. teriflunomide, fingolimod, natalizumab must be discontinued at least 6 weeks prior to study enrollment; for teriflunomide, the SmPC dropout procedure must be followed if the patient requires enrollment in the study between 2-4 weeks after withdrawal;c. ocrelizumab, mitoxantrone, and alemtuzumab must be discontinued for at least 12 months prior to study enrollment. 13. Relapsing-remitting MS 14. Primary progressive form of MS 15. HBV or HCV infection (positive HBV, positive anti-HBc antibodies or positive anti-HCV antibodies) 16. HIV infection or HIV screening positive (anti-HIV 1/2 antibodies, p24 antigen) 17. Active or latent tuberculosis: a positive QuantiFERON TB Gold (QFT) test during screening or in the 3 months prior to screening (inconclusive test should be repeated; two inconclusive tests are considered positive) 18. Other infections that may worsen with cladribine therapy. 19. Lymphopenia during screening (<1,000 / μl), neutrocytopenia (<1,500 / μl) or thrombocytopenia (<150,000 / μl) 20. Clinical significant abnormalities in the ECG examination according to the researcher's opinion 21. Alcohol or drug abuse in the last 12 months 22. Positive serum pregnancy test during screening 23. History of bone marrow or other organ transplantation 24. Treatment with immunoglobulins or plasmapheresis within the 3 months prior to randomization 25. Treatment with another Investigational medicinal product or medical device in the 6 months prior to randomization 26. At least one abnormal test: a.Creatinine> 1.5 x ULN (ULN; may be repeated if 1.5-2.0 x ULN) b. ALT or AST> 2 x ULN (may be repeated if 1.5-3 x ULN) c. Total Bilirubin> 1.5 x ULN (may be repeated if 1-3 x ULN) d. Hemoglobin <9.5 g / dL (can be repeated if 9-9.4 g / dL) 27. Patient is not fully vaccinated against COVID-19, i.e. at least 6 weeks have not elapsed since the last dose of vaccination. 28. Vaccination with any vaccine within less than 6 weeks 29. The patient has not been screened for neoplasms or the tests performed suggest neoplasm or further tests for neoplasm (chest X-ray PA + side for women and men, mammography or ultrasound of breasts for women, cytology for women, PSA for men). 30. Lack of measurable serum levels of anti-varicella / herpes zoster antibodies. 31. Anticoagulant therapy (oral or parenteral) or anti-platelet therapy other than acetylsalicylic acid.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Experimental	Cladribine Subcutaneous Injection	Drug: Cladribine at a dose of 1.8 mg/kg of body weight. Cladribine will be given subcutaneously over 6 visits every 5-6 weeks.
Control	0.9% Chloride Injection Sodium	Comparator: Placebo matched to the subcutaneous injection of cladribine.

Primary Outcome Measures

Name	Time	Method
Percent brain volume change from last cladribine dose (week 26) to end of study (week 122).		Percent brain volume change from last cladribine dose (week 26) to end of study (week 122).

Secondary Outcome Measures

Name	Time	Method
1.Time to 24-week confirmed composite progression of disability defined as the occurrence of any of the following events: an increase in EDSS score, in time of Timed 25-Foot Walk and 9-Hole Peg Test. 2.Change from baseline in cognitive function (CANTAB, CVLT, SDMT) and quality of life (MSQeL-54) 3.Neuroimaging: number of Gd+ lesions, new T2 lesions, QSM rim+ lesions, volume of T1 lesions (black holes), volume of cervical spinal cord in T1; 4. Serum level of NfL, GFAP, oligoclonal bands presence		1.Time to 24-week confirmed composite progression of disability defined as the occurrence of any of the following events: an increase in EDSS score, in time of Timed 25-Foot Walk and 9-Hole Peg Test. 2.Change from baseline in cognitive function (CANTAB, CVLT, SDMT) and quality of life (MSQeL-54) 3.Neuroimaging: number of Gd+ lesions, new T2 lesions, QSM rim+ lesions, volume of T1 lesions (black holes), volume of cervical spinal cord in T1; 4. Serum level of NfL, GFAP, oligoclonal bands presence

Trial Locations

Locations (2)

Instytut Psychiatrii I Neurologii; 🇵🇱 Warsaw, Poland

Wojskowy Instytut Medycyny Lotniczej; 🇵🇱 Warsaw, Poland

Instytut Psychiatrii I Neurologii

🇵🇱Warsaw, Poland

Beata Blazejewska Hyzorek

Site contact

224582537

hyzorek@ipin.edu.pl